Hepatitis/MASH

Most read HCV articles of the year.

Human pegivirus-2 found only in patients with hepatitis C.

Dr. Raymond Schinazi under fire over HCV drug costs.

Study is the first to demonstrate a strong association between HCV and PD.

From the bright lights of Broadway to the darkness of hepatitis C infection, effective new drugs help patient start life anew.

An estimated 500,000 incarcerated people in the US are currently infected with hepatitis C.

Urban caregivers on the front lines of fighting HCV.

Use of these hepatoprotective agents may reduce the risk of liver damage caused by ingredients in Technivie and Viekira Pak.

Research may offer hope for hepatitis C patients with liver disease.

An overview of Daklinza (daclatasvir) for pharmacists.

Panel suggests different regimens for different hepatitis C patient groups.

Hope on the horizon for patients with liver damage.

Researchers seek a better understanding of the mechanism behind hepatocellular carcinoma.

Risk for illness and death greater due to socioeconomic status of patients with hepatitis C.

Gilead alleged to have priced and marketed Sovaldi to maximize revenue without regard to consequences for patients.

Statins show promise to reduce liver disease incidence in coinfected patients.

Traveling a longer distance to a medical center was not associated with spending more time on a waiting list.

Liver conserving treatments are sorely needed.

Research may lead to gel that prevents transmission of HIV, hepatitis C and the Ebola virus.

An HCV vaccine, while elusive, offers the best hope to eradicate the virus.

Eating before bed can have a significant impact on the development of nonalcoholic fatty liver disease.

Researchers consider the ramifications of using organs from infected patients to save lives.

Liver damage caused by hepatitis C may eventually be overcome through stem cell therapy.

Enhanced screening and treatment in high-risk populations could eliminate virus.